ArticleOncotarget2017
Homeobox A11 hypermethylation indicates unfavorable prognosis in breast cancer.
Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.
- Genome-wide association study of germline variants and breast cancer-specific mortality.British journal of cancer · 2019Pooled it
- Tumor and serum DNA methylation in women receiving preoperative chemotherapy with or without vorinostat in TBCRC008.Breast cancer research and treatment · 2018Trial
- Multifaceted regulation of the HOX cluster and its implications in oral cancer.Clinical epigenetics · 2025Article
- Toll-like receptors in breast cancer immunity and immunotherapy.Frontiers in immunology · 2024Review
- Upregulation of TLR5 indicates a favorable prognosis in prostate cancer.The Prostate · 2023Article
- Molecular implications of HOX genes targeting multiple signaling pathways in cancer.Cell biology and toxicology · 2022Review
- Article
- Association of variably methylated tumour DNA regions with overall survival for invasive lobular breast cancer.Clinical epigenetics · 2021Article
- Methylation inCells · 2020Review
- The "Janus Face" of Platelets in Cancer.International journal of molecular sciences · 2020Review
- Bioinformatics analysis of the expression of HOXC13 and its role in the prognosis of breast cancer.Oncology letters · 2020Article
- An inverse interaction betweenEpigenetics · 2019Article
- Thrombocytopenia in solid tumors: Prognostic significance.Oncology reviews · 2019Article
- Upregulation of HOXA11 during the progression of lung adenocarcinoma detected via multiple approaches.International journal of molecular medicine · 2018Article
- Evaluation of the HOXA11 level in patients with lung squamous cancer and insights into potential molecular pathways via bioinformatics analysis.World journal of surgical oncology · 2018Article
- The landscape of DNA methylation-mediated regulation of long non-coding RNAs in breast cancer.Oncotarget · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 2 countries.
Funding
Abstract
Homeobox A11 (HOXA11) is one of the hypermethylated genes in breast cancer and its function in breast tumorigenesis remains elusive. In this study, we analyzed the methylation status of HOXA11 in 264 paired breast cancer and normal tissue as well as in matched serum samples by MethyLight assay. Further, the function of HOXA11 in breast tumorigenesis was analyzed by cell proliferation and migration assays. We found that HOXA11 was hypermethylated in cancer tissues (45.08%), especially in invasive ductal carcinomas (P<0.001), patients with a family history of cancer (P=0.033), cases with metastatic lymph nodes (P=0.004) and P53 positive group (P=0.017). Kaplan-Meier survival analysis and Cox regression analysis revealed that HOXA11 hypermethylation is an independent predictor of poor outcomes. The over expression of HOXA11 suppressed cell growth in MDA-MB-231, MCF7, SKBR3 and BT474 cells. In conclusion, the hypermethylation of HOXA11 is an independent prognostic biomarker in breast cancer. Additionally, HOXA11 can be a potential tumor suppressor.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.